Loading company…
NGGT develops genetic medicines and related therapies.
NGGT develops gene therapies for viral infections and conditions affecting the blood, eyes, and nervous system. Its products include NGGT001 for retinitis pigmentosa and NGGT002 for metabolic diseases. Based in Suzhou, China, it raised USD 40 million in Series B funding in July 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in